MediBeacon's Transdermal GFR Monitor and Sensor approved by China NMPA; Lumitrace under review

INNOVATE Corp.

China NMPA approved MediBeacon TGFR Monitor and Sensor for kidney function assessment; Lumitrace injection still under review, target approval late 2025.
FDA approved the TGFR system on Jan 17, 2025; MediBeacon developing next-gen TGFR with updated software.
Published studies: eGFR misclassified 35% of CKD patients; transdermal GFR showed r²=0.90 correlation with plasma mGFR across skin types.
MediBeacon CEO highlighted partnership with Huadong Medicine for China rollout of the TGFR system.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.